Why cell therapy manufacture is a team sportLouis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that Share XWhy cell therapy manufacture is a team sporthttps://pharmaphorum.com/market-access-2/why-cell-therapy-manufacture-is-a-team-sport/
The calm after the storm: How COVID-19 is making pharma more resilientCOVID-19 is proving to be the perfect storm in terms of the supply of pharmaceutical products. But learning Share XThe calm after the storm: How COVID-19 is making pharma more resilienthttps://pharmaphorum.com/views-analysis-sales-marketing/the-calm-after-the-storm-how-covid19-is-making-pharma-more-resilient-and-accessible/
Germany’s digital health changes will boost digital therapeutics in EuropeDigital therapeutics are gaining momentum worldwide and offer developers, including pharma, both a huge opportunity and a stimulating Share XGermany’s digital health changes will boost digital therapeutics in Europehttps://deep-dive.pharmaphorum.com/magazine/digital-health-innovation-2020/germanys-digital-health-changes-will-boost-digital-therapeutics/
EMA starts rapid review of Bluebird’s gene therapy for rare disease CALDBluebird bio could be just a few months away from approval of its gene therapy for rare disease Share XEMA starts rapid review of Bluebird’s gene therapy for rare disease CALDhttps://pharmaphorum.com/news/ema-starts-rapid-review-of-bluebirds-gene-therapy-for-rare-disease-cald/
Life science leaders sign new ‘Biotech Social Pact’ for EuropeThe signatories of a new Biotech Social Pact with Europe and patients explain why healthcare calls for a Share XLife science leaders sign new ‘Biotech Social Pact’ for Europehttps://pharmaphorum.com/views-analysis-market-access/life-science-leaders-sign-new-biotech-social-pact-for-europe/
Time for a health innovation pact: rethinking the design and delivery of healthcareJanssen’s Anouk De Vroey on why we need to extend the public/private partnerships resulting from COVID-19 into more Share XTime for a health innovation pact: rethinking the design and delivery of healthcarehttps://pharmaphorum.com/views-and-analysis/time-for-a-health-innovation-pact-rethinking-the-design-and-delivery-of-healthcare/
How does HTA for orphan drugs differ across Europe?New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines Share XHow does HTA for orphan drugs differ across Europe?https://pharmaphorum.com/views-analysis-market-access/how-does-hta-for-orphan-drugs-differ-across-europe/
New digital health player HealthHero launches with Fernarzt buyThere’s a new kid on the block in digital health – called HealthHero – with aspirations to become Share XNew digital health player HealthHero launches with Fernarzt buyhttps://pharmaphorum.com/news/new-digital-health-player-healthhero-launches-with-fernarzt-buy/
Alnylam’s Anant Murthy on making it as a US biotech in EuropeAlnylam’s European head of market access and GM of mid-size markets, Anant Murthy, shares his perspective on how Share XAlnylam’s Anant Murthy on making it as a US biotech in Europehttps://pharmaphorum.com/r-d/views-analysis-r-d/alnylam-anant-murthy-on-making-it-as-a-us-biotech-in-europe/
